Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins... Show more
A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ARVN | 1D Price Change % | ||
|---|---|---|---|---|
| ARVN | 100% | -5.44% | ||
| AXON - ARVN | 46% Loosely correlated | +1.39% | ||
| KURA - ARVN | 46% Loosely correlated | -2.54% | ||
| VCYT - ARVN | 46% Loosely correlated | +4.11% | ||
| STOK - ARVN | 46% Loosely correlated | -2.57% | ||
| XNCR - ARVN | 46% Loosely correlated | -2.55% | ||
More | ||||
a developer of therapies to degrade disease-causing proteins
Industry Biotechnology
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 43 cases where ARVN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 21 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for ARVN just turned positive on October 19, 2026. Looking at past instances where ARVN's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 79 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for ARVN crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.849) is normal, around the industry mean (3.035). P/E Ratio (24.333) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.